Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: old-fashioned (3), old (260), square (21)

DART study privacy notice

Description: Your role in improving the diagnosis of lung disease Information Sheet and Privacy Notice Oxford University is leading a project to
Url: /Media/UHS-website-2019/Docs/Services/Blood-heart-and-circulation/DART-study-privacy-notice.pdf

Botox treatment for bladder problems - Patient initiated follow-up (PIFU) - patient information

Description: This factsheet contains contact information for people who are receiving Botox treatment for bladder problems so that they can arrange a
Url: /Media/UHS-website-2019/Patientinformation/Womenshealth/Botox-treatment-for-bladder-problems-Patient-initiated-follow-up-PIFU-1423-PIL.pdf

Vismodegib

Description: Chemotherapy Protocol BASAL CELL CARCINOMA (BCC) VISMODEGIB Regimen  BCC - Vismodegib Indication  The patient either has; a. Gorlin Syndrome with non-locally
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Vismodegib.pdf

Lorlatinib

Description: A document based on Lorlatinib, a lung cancer condition.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Lorlatinib.pdf

Magnetic resonance imaging (MRI) cardiac stress scan (adenosine or dobutamine) - patient information

Description: This factsheet contains information about a having a cardiac MRI stress scan with adenosine or dobutamine.
Url: /Media/UHS-website-2019/Patientinformation/Scansandx-rays/Magnetic-resonance-imaging-MRI-cardiac-stress-scan-adenosine-or-dobutamine-3147-PIL.pdf

EDI Strategy Workshops 2022

Description: Get Involved. Have your say. Help develop the Diversity and Inclusion Strategy for UHS. You are invited to join a series
Url: /Media/Southampton-Clinical-Research/Downloads/EDI-Strategy-Workshops-2022.pdf

Vinorelbine (oral day 1, 8 and 15)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) VINORELBINE (Oral) (Day 1, 8, 15) This protocol may require funding Regimen NSCLC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Vinorelbineoralday18and15ver11.pdf

Vinorelbine (oral day 1 and 8)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) VINORELBINE (Oral) (Day 1 and 8) This protocol may require funding Regimen NSCLC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Vinorelbineoralday1and8ver11.pdf

UHS support timeline for fellowships_2021

Description: UHS personal fellowship submissions Guidance on where to start, timelines and finding support Up to 1 year • Pre-submission preparations •decide
Url: /Media/Southampton-Clinical-Research/Grants/Download/UHS-support-timeline-for-fellowships-2021.pdf

Olaparib Tablets

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCERS OLAPARIB (tablets) This regimen may require funding. Regimen • Ovarian Cancer – Olaparib (tablets) Indication • Olaparib in its tablet
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Olaparib-Tablets.pdf

431 to 440 of 1000

Previous … 42 43 44 45 46 … Next